Journal article
Topiramate for smoking cessation.
- Khazaal Y University Department of Adult Psychiatry, Prilly, and Department of Community Medicine and Public Health, University Hospital, Lausanne, Switzerland. yasser.khazaal@hospvd.ch
- Cornuz J
- Bilancioni R
- Zullino DF
- 2006-05-31
Published in:
- Psychiatry and clinical neurosciences. - 2006
Adult
Behavior, Addictive
Female
Fructose
Humans
Male
Middle Aged
Neuroprotective Agents
Pilot Projects
Receptors, AMPA
Smoking Cessation
Smoking Prevention
Topiramate
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
English
Due to its AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate antagonism, topiramate would be particularly interesting in addiction treatment. Flexible-dose topiramate was prescribed to 13 smokers (10 smokers who wanted to stop smoking, and three who received topiramate for other reasons). Six out of 13 smokers were abstinent at 2 months and two more subjects had reduced their cigarette consumption by >50%. With one exception, temporary reduction of the number of smoked cigarettes preceded definitive abstinence at month 2. Three more subjects who achieved a momentary reduction had, however, to interrupt the treatment due to intolerable side-effects. Controlled trials are needed to confirm these preliminary observations.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1111/j.1440-1819.2006.01518.x
- PMID 16732758
- Persistent URL
- https://sonar.ch/global/documents/98848
Statistics
Document views: 28
File downloads: